QPF · Pediatric Autism Spectrum Disorder Diagnosis Aid
Neurology · 21 CFR 882.1491 · Class 2
Overview
| Product Code | QPF |
|---|---|
| Device Name | Pediatric Autism Spectrum Disorder Diagnosis Aid |
| Regulation | 21 CFR 882.1491 |
| Device Class | Class 2 |
| Review Panel | Neurology |
Identification
A pediatric Autism Spectrum Disorder diagnosis aid is a prescription device that is intended for use as an aid in the diagnosis of Autism Spectrum Disorder in pediatric patients.
Classification Rationale
Class II (special controls). The special controls for this device are:
Special Controls
In combination with the general controls of the FD&C Act, the pediatric Autism Spectrum Disorder diagnosis aid is subject to the following special controls: - (1) Clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use, including an evaluation of sensitivity, specificity, positive predictive value, and negative predictive value using a reference method of diagnosis and assessment of patient behavioral symptomology. - (2) Software verification, validation, and hazard analysis must be provided. Software documentation must include a detailed, technical description of the algorithm(s) used to generate device output(s), and a cybersecurity assessment of the impact of threats and vulnerabilities on device functionality and user(s). - (3) Usability assessment must demonstrate that the intended user(s) can safely and correctly use the device. - (4) Labeling must include: - (i) Instructions for use, including a detailed description of the device, compatibility information, and information to facilitate clinical interpretation of all device outputs: - (ii) A summary of any clinical testing conducted to demonstrate how the device functions as an interpretation of patient behavioral symptomology associated with Autism Spectrum Disorder. The summary must include the following: - (A) A description of each device output and clinical interpretation; - (B) Any performance measures, including sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV); - (C) A description of how the cut-off values used for categorical classification of diagnoses were determined; and - (D) Any expected or observed adverse events and complications. (iii)A statement that the device is not intended for use as a stand-alone diagnostic.
*Classification.* Class II (special controls). The special controls for this device are:(1) Clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use, including an evaluation of sensitivity, specificity, positive predictive value, and negative predictive value using a reference method of diagnosis and assessment of patient behavioral symptomology. (2) Software verification, validation, and hazard analysis must be provided. Software documentation must include a detailed, technical description of the algorithm(s) used to generate device output(s), and a cybersecurity assessment of the impact of threats and vulnerabilities on device functionality and user(s). (3) Usability assessment must demonstrate that the intended user(s) can safely and correctly use the device. (4) Labeling must include: (i) Instructions for use, including a detailed description of the device, compatibility information, and information to facilitate clinical interpretation of all device outputs; and (ii) A summary of any clinical testing conducted to demonstrate how the device functions as an interpretation of patient behavioral symptomology associated with Autism Spectrum Disorder. The summary must include the following: (A) A description of each device output and clinical interpretation; (B) Any performance measures, including sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV); (C) A description of how the cutoff values used for categorical classification of diagnoses were determined; and (D) Any expected or observed adverse events and complications. (iii) A statement that the device is not intended for use as a stand-alone diagnostic.
Recent Cleared Devices (6 of 6)
| Record | Device Name | Applicant | Decision Date | Decision |
|---|---|---|---|---|
| K253442 | EarliPoint Assessment | Earlitec Diagnostics | Mar 5, 2026 | SESE |
| K243558 | Canvas Dx | Cognoa, Inc. | Apr 11, 2025 | SESE |
| K243891 | EarliPoint System | Earlitec Diagnostics | Mar 26, 2025 | SESE |
| K230337 | EarliPoint | Earlitec Diagnostics, Inc. | Jun 29, 2023 | SESE |
| K213882 | EarliPoint System | Earlitec Diagnostics, Inc. | Jun 8, 2022 | SESE |
| DEN200069 | Cognoa ASD Diagnosis Aid | Cognoa, Inc. | Jun 2, 2021 | DENG |
Top Applicants
- Cognoa, Inc. — 2 clearances
- Earlitec Diagnostics — 2 clearances
- Earlitec Diagnostics, Inc. — 2 clearances